news
Heart drugs free from carcinogens identified as recalls drag on
The Food and Drug Administration has released a list of 40 drugs used to treat hypertension and heart failure that don’t contain any known carcinogens...
List view / Grid view
Generics
news
New generic valsartan approved to address shortages
The FDA has prioritised the review of this drug application after multiple recalls of generic valsartan products from several manufacturers...
news
Indian government plans to colour code generics
Colour-coded generics might help consumers differentiate between generics and branded medicines...
news
EU measures in support of generic pharmaceuticals producers
The EU is adopting new rules which should boost the competitiveness of EU producers of generic medicines and biosimilar products...
news
FDA grant to help increase generic drugs delivered intravaginally or by IUD
Of the 21 drugs designed for delivery directly to the female genital tract, only four have a cost-effective, generic equivalent...
news
Rising drug prices linked to older products, study finds
The rising costs of brand-name drugs is largely driven by inflation in the prices of widely used existing drugs, according to a study published in the January issue of Health Affairs...
news
Pharmaceutical glass packaging market to grow at 6% CAGR
North America dominates the global market for pharmaceutical glass packaging, due to the region’s technical innovation and strong demand for pharmaceutical products...
news
FDA approves first generic versions of Suboxone for opioid dependence
The FDA has approved the first generic versions of Suboxone sublingual film for the treatment of opioid dependence...
news
Generic antiplatelet drugs are as effective as brand name counterpart
A study in Canada has demonstrated that generic antiplatelet drugs appear to be as equally effective as a brand name drug for heart patients.
news
FDA approves Glatopa a generic option for relapsing forms of multiple sclerosis
Sandoz has announced that the FDA has approved and launch of Glatopa as a fully-substitutable, AP-rated generic version of Copaxone for relapsing forms of MS...
news
Report identifies two-tier pharmaceuticals market
A report released has identified a two-tier manufacturing market and forecast increased acquisitions by Indian companies...
news
HerpV and GEN-003 will drive genital herpes treatment market growth to 2023
21 July 2015 | By Victoria White
The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period, says research and consulting firm GlobalData.
